Research graph
References from Ibalizumab: a comprehensive review of a pioneering monoclonal antibody therapy in the management of HIV/AIDS. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Advancing the Global Fight Against HIV/Aids: Strategies, Barriers, and the Road to Eradication
10.5334/aogh.4277 · 2023 · External reference
Origins of HIV and the AIDS pandemic
10.1101/cshperspect.a006841 · 2011 · External reference
Past, present and future: 30 years of HIV research
10.1038/nrmicro3132 · 2013 · External reference
HIV: progress and future challenges in treatment, prevention and cure
2018 · External reference
Preventing HIV antiretroviral resistance through better monitoring of treatment adherence
10.1086/533415 · 2008 · External reference
Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults
10.1128/aac.00942-08 · 2009 · External reference
Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection
10.1128/aac.00110-19 · 2019 · External reference
Ibalizumab: First Global Approval
10.1007/s40265-018-0907-5 · 2018 · External reference
Unresolved reference
External reference
A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV
10.1177/87551225241259894 · 2024 · External reference
Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients
10.1128/jvi.00453-10 · 2010 · External reference
Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope
10.1097/qai.0b013e3182732746 · 2013 · External reference
Unresolved reference
External reference
The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment
10.1016/j.antiviral.2011.09.010 · 2011 · External reference
Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection
10.1177/1060028020942218 · 2021 · External reference
GSK3732394: a Multi-specific Inhibitor of HIV Entry
10.1128/jvi.00907-19 · 2019 · External reference
Pharmacological advances in anti-retroviral therapy for human immunodeficiency virus-1 infection: A comprehensive review
10.1002/rmv.2529 · 2024 · External reference
Future of bNAbs in HIV Treatment
10.1007/s11904-025-00744-1 · 2025 · External reference
Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study
10.1097/qai.0000000000002591 · 2021 · External reference
Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection
10.1016/j.jval.2018.04.062 · 2018 · External reference
Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study
10.1080/19420862.2022.2156317 · 2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody
10.4049/jimmunol.149.5.1779 · 1992 · External reference
Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies
10.1128/jvi.77.1.353-365.2003 · 2003 · External reference
Humanized mice for HIV and AIDS research
10.1016/j.coviro.2016.06.010 · 2016 · External reference
Humanized Mice for Studies of HIV-1 Persistence and Elimination
10.3390/pathogens12070879 · 2023 · External reference
Unresolved reference
External reference
Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1
10.1086/380802 · 2004 · External reference
Long-Term Efficacy, Safety, and Durability of Ibalizumab-Based Regimens in Subgroup of TMB-202 Participants
10.1093/ofid/ofaa439.1213 · 2020 · External reference
Ibalizumab
10.1097/coh.0000000000000473 · 2018 · External reference
Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)
10.1093/ofid/ofz360.729 · 2019 · External reference
Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection
10.1007/s40265-020-01258-3 · 2020 · External reference
Real-World Use of Ibalizumab in Physician Office Infusion Centers (POICs)
10.1093/ofid/ofz360.2172 · 2019 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
A regression approach for assessing large molecular drug concentration in breast milk
10.1016/j.repbre.2023.10.003 · 2023 · External reference
Monoclonal Antibodies During Breastfeeding
10.1089/bfm.2021.0110 · 2021 · External reference
Reducing HIV-related stigma and discrimination in healthcare settings: A systematic review of quantitative evidence
10.1371/journal.pone.0211298 · 2019 · External reference
The Role of Stigma Management in HIV Treatment Adherence
10.3390/ijerph16245003 · 2019 · External reference
Social stigma concerns and HIV medication adherence
10.1089/apc.2006.20.359 · 2006 · External reference
Unresolved reference
External reference
Long-acting injectable antiretrovirals for HIV treatment and prevention
10.1097/coh.0000000000000002 · 2013 · External reference
Implementing ‘universal’ access to antiretroviral treatment in South Africa: a scoping review on research priorities
10.1093/heapol/czaa094 · 2021 · External reference
Unresolved reference
External reference
Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir
10.1093/infdis/jiac364 · 2022 · External reference
Ibalizumab in Multidrug-Resistant HIV - Accepting Uncertainty
10.1056/nejmp1808729 · 2018 · External reference
Pharmacological advances in anti-retroviral therapy for human immunodeficiency virus-1 infection: A comprehensive review
10.1002/rmv.2529 · ExternalCitation · doi-reference
Future of bNAbs in HIV Treatment
10.1007/s11904-025-00744-1 · ExternalCitation · doi-reference
Ibalizumab: First Global Approval
10.1007/s40265-018-0907-5 · ExternalCitation · doi-reference
Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection
10.1007/s40265-020-01258-3 · ExternalCitation · doi-reference
The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment
10.1016/j.antiviral.2011.09.010 · ExternalCitation · doi-reference
Humanized mice for HIV and AIDS research
10.1016/j.coviro.2016.06.010 · ExternalCitation · doi-reference
Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection
10.1016/j.jval.2018.04.062 · ExternalCitation · doi-reference
A regression approach for assessing large molecular drug concentration in breast milk
10.1016/j.repbre.2023.10.003 · ExternalCitation · doi-reference
Past, present and future: 30 years of HIV research
10.1038/nrmicro3132 · ExternalCitation · doi-reference
Ibalizumab in Multidrug-Resistant HIV - Accepting Uncertainty
10.1056/nejmp1808729 · ExternalCitation · doi-reference
Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study
10.1080/19420862.2022.2156317 · ExternalCitation · doi-reference
Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1
10.1086/380802 · ExternalCitation · doi-reference
Preventing HIV antiretroviral resistance through better monitoring of treatment adherence
10.1086/533415 · ExternalCitation · doi-reference
Social stigma concerns and HIV medication adherence
10.1089/apc.2006.20.359 · ExternalCitation · doi-reference
Monoclonal Antibodies During Breastfeeding
10.1089/bfm.2021.0110 · ExternalCitation · doi-reference
Implementing ‘universal’ access to antiretroviral treatment in South Africa: a scoping review on research priorities
10.1093/heapol/czaa094 · ExternalCitation · doi-reference
Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir
10.1093/infdis/jiac364 · ExternalCitation · doi-reference
Long-Term Efficacy, Safety, and Durability of Ibalizumab-Based Regimens in Subgroup of TMB-202 Participants
10.1093/ofid/ofaa439.1213 · ExternalCitation · doi-reference
Real-World Use of Ibalizumab in Physician Office Infusion Centers (POICs)
10.1093/ofid/ofz360.2172 · ExternalCitation · doi-reference
Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)
10.1093/ofid/ofz360.729 · ExternalCitation · doi-reference
Long-acting injectable antiretrovirals for HIV treatment and prevention
10.1097/coh.0000000000000002 · ExternalCitation · doi-reference
Ibalizumab
10.1097/coh.0000000000000473 · ExternalCitation · doi-reference
Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study
10.1097/qai.0000000000002591 · ExternalCitation · doi-reference
Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope
10.1097/qai.0b013e3182732746 · ExternalCitation · doi-reference
Origins of HIV and the AIDS pandemic
10.1101/cshperspect.a006841 · ExternalCitation · doi-reference
Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection
10.1128/aac.00110-19 · ExternalCitation · doi-reference
Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults
10.1128/aac.00942-08 · ExternalCitation · doi-reference
Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients
10.1128/jvi.00453-10 · ExternalCitation · doi-reference
GSK3732394: a Multi-specific Inhibitor of HIV Entry
10.1128/jvi.00907-19 · ExternalCitation · doi-reference
Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies
10.1128/jvi.77.1.353-365.2003 · ExternalCitation · doi-reference
Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection
10.1177/1060028020942218 · ExternalCitation · doi-reference
A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV
10.1177/87551225241259894 · ExternalCitation · doi-reference
Reducing HIV-related stigma and discrimination in healthcare settings: A systematic review of quantitative evidence
10.1371/journal.pone.0211298 · ExternalCitation · doi-reference
The Role of Stigma Management in HIV Treatment Adherence
10.3390/ijerph16245003 · ExternalCitation · doi-reference
Humanized Mice for Studies of HIV-1 Persistence and Elimination
10.3390/pathogens12070879 · ExternalCitation · doi-reference
Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody
10.4049/jimmunol.149.5.1779 · ExternalCitation · doi-reference
Advancing the Global Fight Against HIV/Aids: Strategies, Barriers, and the Road to Eradication
10.5334/aogh.4277 · ExternalCitation · doi-reference
